Cost Effectiveness Decisions Playing Greater Role In Off-Label Coverage
The role of cost analysis in the context of comparative effectiveness research has been hotly contested, but cost effectiveness is already gaining importance as a factor in how third-party payers run Medicare and Medicaid prescription drug plans
You may also be interested in...
A debate is brewing over how Medicare should handle plans' step-therapy practices that encourage beneficiaries to try an off-label treatment before coverage is granted for a drug with an FDA-approved indication
The U.S. will not follow the UK’s model of having a bureaucratic organization making cost-effectiveness decisions, OMB director tells Congress.
Even with the inclusion of comparative effectiveness research funding in the American Recovery and Reinvestment Act, Senate Finance Committee Chairman Max Baucus is showing no signs of abandoning plans to include comparative effectiveness in the upcoming health care reform debate